DT-168

About Design Therapeutics

Design Therapeutics is a clinical-stage biotech focused on developing disease-modifying therapies for severe genetic disorders driven by nucleotide repeat expansions. Its core innovation is the GeneTAC™ platform, which creates bifunctional small molecules that can precisely upregulate or downregulate disease-causing genes without altering DNA. The company's strategy targets monogenic diseases with high unmet need, advancing a pipeline led by DT-216P2 for Friedreich's ataxia, now in Phase 1/2 trials, alongside preclinical programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1.

Therapeutic Areas